Processing

Please wait...

Settings

Settings

Goto Application

1. WO2005101008 - DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH RETINOID X RECEPTOR GAMMA (RXRG)

Publication Number WO/2005/101008
Publication Date 27.10.2005
International Application No. PCT/EP2005/003469
International Filing Date 02.04.2005
IPC
G01N 33/574 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
574for cancer
G01N 33/68 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68involving proteins, peptides or amino acids
CPC
G01N 2500/00
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2500Screening for compounds of potential therapeutic value
G01N 33/6875
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68involving proteins, peptides or amino acids
6875Nucleoproteins
Applicants
  • BAYER HEALTHCARE AG [DE]/[DE] (AllExceptUS)
  • GOLZ, Stefan [DE]/[DE] (UsOnly)
  • BRÜGGEMEIER, Ulf [DE]/[DE] (UsOnly)
  • GEERTS, Andreas [DE]/[DE] (UsOnly)
Inventors
  • GOLZ, Stefan
  • BRÜGGEMEIER, Ulf
  • GEERTS, Andreas
Common Representative
  • BAYER HEALTHCARE AG
Priority Data
04008926.015.04.2004EP
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH RETINOID X RECEPTOR GAMMA (RXRG)
(FR) DIAGNOSTICS ET THERAPEUTIQUES POUR TRAITER DES MALADIES ASSOCIEES AU RECEPTEUR GAMMA DE RETINOIDE X (RXRG)
Abstract
(EN)
The invention provides a human RXRG which is associated with the infections, cardiovascular diseases, endocrinological diseases, metabolic diseases, cancer, gastroenterological diseases, inflammation, hematological diseases, respiratory diseases, muscle skeleton diseases, neurological diseases and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of infections, cardiovascular diseases, endocrinological diseases, metabolic diseases, cancer, gastroenterological diseases, inflammation, hematological diseases, respiratory diseases, muscle skeleton diseases, neurological diseases and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of RXRG as well as pharmaceutical compositions comprising such compounds.
(FR)
L'invention concerne un RXRG humain qui est associé à des infections, des maladies cardio-vasculaires, des maladies endocrinologiques, des maladies métaboliques, des cancers, des maladies gastro-entologiques, des inflammations, des maladies hématologiques, des maladies respiratoires, des maladies squeletto-musculaires, des maladies neurologiques et des maladies urologiques. Cette invention porte également sur des épreuves biologiques pour l'identification de composés utiles dans le traitement ou la prévention d'infections, de maladies cardio-vasculaires, de maladies endocrinologiques, de maladies métaboliques, de cancers, de maladies gastro-entologiques, d'inflammations, de maladies hématologiques, de maladies respiratoires, de maladies squeletto-musculaires, de maladies neurologiques et de maladies urologiques. Cette invention concerne aussi des composés qui se lient à RXRG et/ou activent ou inhibent l'activité de RXRG, ainsi que des compositions pharmaceutiques contenant ces composés.
Latest bibliographic data on file with the International Bureau